Medicine and Dentistry
Patient
100%
Psoriasis
87%
Therapeutic Procedure
57%
Combination Therapy
21%
Psoriasis Vulgaris
20%
Diseases
19%
Psoriatic Arthritis
16%
Biological Product
16%
Inpatient
13%
Tumor Necrosis Factor
12%
Drug
11%
Tumor Necrosis Factor
11%
Chemotherapeutic Agent
11%
Adverse Event
10%
Hidradenitis Suppurativa
10%
Inflammatory Bowel Disease
10%
Transplantation
9%
Skin Defect
9%
Atopic Dermatitis
9%
Skin
9%
Bullous Pemphigoid
9%
Dupilumab
9%
Prevalence
9%
Dermatosis
9%
Systemic Therapy
9%
Quality of Life
8%
Erythema Nodosum
8%
Woman
8%
Risankizumab
7%
Age
7%
Diagnosis
7%
Experience
7%
Pyoderma gangrenosum
7%
Nail Psoriasis
7%
Case Report
7%
TNF Inhibitor
7%
Biological Therapy
7%
Lesion
6%
Pustulosis Palmaris Et Plantaris
6%
Life
6%
Association
6%
Cytokine
6%
Immunosuppressive Treatment
6%
Tildrakizumab
6%
Polycystic Ovary Syndrome
6%
Psoriasis Area and Severity Index
5%
Consensus
5%
Serositis
5%
Toxic Epidermal Necrolysis
5%
Graft Rejection
5%
Nursing and Health Professions
Psoriasis
25%
Patient
24%
Inpatient
11%
Psoriasis Vulgaris
8%
Biological Product
7%
Ixekizumab
7%
Psoriasis Area and Severity Index
6%
Psoriatic Arthritis
5%
Drug
5%
Secukinumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
40%
Drug
8%
Psoriasis
7%
Psoriasis Vulgaris
7%
Biological Product
7%
Adverse Event
6%
Diseases
6%
Tumor Necrosis Factor
6%
Etanercept
5%
Atopic Dermatitis
5%
Adalimumab
5%
